<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059629</url>
  </required_header>
  <id_info>
    <org_study_id>CR014</org_study_id>
    <nct_id>NCT02059629</nct_id>
  </id_info>
  <brief_title>Eluna Family / Sentus BP Master Study</brief_title>
  <official_title>Eluna Family / Sentus BP Master Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Eluna Family / Sentus BP Master Study is designed to confirm the safety of the new Eluna
      pacemaker family and the Sentus BP (bipolar) left ventricular lead.

      Furthermore the new wandless RF telemetry function &quot;SafeSync&quot; and the handling of the Sentus
      lead during implantation will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Eluna pacemaker family: Serious Adverse Device Effect (SADE) - free rate</measure>
    <time_frame>6 months</time_frame>
    <description>The safety of the Eluna pacemaker family will be evaluated by asking the investigator to record any adverse event. While all adverse events have to be recorded throughout the study, only the number of SADEs possibly or securely related to the pacemaker will be the basis for endpoint calculation of the SADE-free rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sentus BP lead: Serious Adverse Device Effect (SADE) - free rate</measure>
    <time_frame>3 months</time_frame>
    <description>The safety of the Sentus BP left ventricular lead will be evaluated by asking the investigator to record any adverse event. While all adverse events have to be recorded throughout the study, only the number of SADEs possibly or securely related to the Sentus BP lead will be the basis for endpoint calculation of the SADE free rate.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Collection of data of interest: Handling assessment of Sentus lead during implantation</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Collection of further data of interest: Evaluation of wandless RF telemetry function &quot;SafeSync&quot; in the Eluna pacemaker family</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">167</enrollment>
  <condition>Bradycardia</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Group A: Eluna pacemaker family</arm_group_label>
    <description>Patients with standard indication for pacemaker therapy or Cardiac Resynchronization Therapy (CRT), who will be implanted with a pacemaker or CRT device of the Eluna pacemaker family. Single-, Dual- and Tripple-chamber pacemakers are applicable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Sentus BP lead</arm_group_label>
    <description>Heart failure patients with indication for Cardiac Resynchronization Therapy (CRT) therapy, who will be implanted with the left ventricular Sentus BP lead. Patients can receive either CRT pacemaker or CRT-D (CRT with defibrillator function).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eluna pacemaker family</intervention_name>
    <description>New pacemaker generation with new functions, like wandless RF telemetry &quot;SafeSync&quot;</description>
    <arm_group_label>Group A: Eluna pacemaker family</arm_group_label>
    <other_name>Eluna SR-T/DR-T/HF-T</other_name>
    <other_name>Etrinsa SR-T/DR-T/HF-T</other_name>
    <other_name>Epyra SR-T/DR-T/HF-T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sentus BP lead</intervention_name>
    <description>over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead</description>
    <arm_group_label>Group B: Sentus BP lead</arm_group_label>
    <other_name>Sentus OTW BP L</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from available pacemaker or CRT patients directly by the
        treating physician at the investigational site
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is willing to participate in the study and provided written informed consent

          -  Patient meets standard indication for pacemaker or CRT-P or CRT-D therapy

          -  Patient accepts Home Monitoring® concept

          -  Patient has legal capacity and ability to consent

        Exclusion Criteria:

          -  Patient with any contraindication to pacemaker and CRT-P and CRT-D therapy

          -  Patient under the age of 18

          -  Pregnant or breast-feeding women

          -  Cardiac surgery planned within the next 6 months

          -  Life expectancy less than 12 months

          -  Participation in another cardiac clinical investigation with active treatment arm

          -  Group B only: Currently implanted with an endocardial or epicardial LV lead or had
             prior attempt to place a LV lead (for CRT implants only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges Mairesse, Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques du Sud Luxembourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques du Sud Luxembourg</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL Genk</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, CBF: Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, CVK: Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Medizinische Klinik 2</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Westdeutsches Herzzentrum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital Lünen</name>
      <address>
        <city>Lünen</city>
        <zip>44534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhaus GmbH St. Elisabeth Krankenhaus Saarlouis</name>
      <address>
        <city>Saarlouis</city>
        <zip>66740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hong Kong</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Eluna pacemaker family</keyword>
  <keyword>Sentus OTW BP L left ventricular lead</keyword>
  <keyword>Bradycardia</keyword>
  <keyword>SADE-free rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

